1
|
Birk H, Kandregula S, Cuevas-Ocampo A, Wang CJ, Kosty J, Notarianni C. Pediatric pituitary adenoma and medulloblastoma in the setting of p53 mutation: case report and review of the literature. Childs Nerv Syst 2022; 38:1783-1789. [PMID: 35254474 DOI: 10.1007/s00381-022-05478-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/25/2021] [Accepted: 02/26/2022] [Indexed: 11/29/2022]
Abstract
Li-Fraumeni syndrome is a cancer predisposition condition associated with various tumor types. We present the case of a 6-year-old boy who initially presented with a pituitary adenoma that was successfully treated with surgery. It ultimately recurred, requiring further surgical intervention followed by proton beam therapy. He later developed a medulloblastoma, and genetic testing revealed TP53 germline mutation. The patient underwent gross total resection of this medulloblastoma, followed by proton-based craniospinal irradiation and adjuvant chemotherapy. He remained disease-free 12 months after radiation and 7 months after chemotherapy. Current literature does not report pituitary adenoma as the initial central nervous manifestation in Li-Fraumeni syndrome. Early genetic testing should be considered in pediatric patients who present with such rare tumor types to help identify cancer predisposing conditions. Furthermore, as evidenced by our case, the management of multiple brain tumors in the pediatric population poses challenges. A multidisciplinary approach involving neurosurgery, pediatric oncology, pathology, and radiation oncology remains crucial to optimize patient outcomes.
Collapse
Affiliation(s)
- H Birk
- Department of Neurosurgery, Louisiana State University Health Shreveport School of Medicine, 1501 Kings Highway, 3-408C, Shreveport, LA, 71105, USA.
| | - S Kandregula
- Department of Neurosurgery, Louisiana State University Health Shreveport School of Medicine, 1501 Kings Highway, 3-408C, Shreveport, LA, 71105, USA
| | - A Cuevas-Ocampo
- Department of Pathology, Louisiana State University Health Shreveport School of Medicine, Shreveport, LA, USA
| | - C Jake Wang
- Department of Radiation Oncology, Willis-Knighton Health System, Shreveport, LA, USA
| | - J Kosty
- Department of Neurosurgery, Louisiana State University Health Shreveport School of Medicine, 1501 Kings Highway, 3-408C, Shreveport, LA, 71105, USA
| | - C Notarianni
- Department of Neurosurgery, Louisiana State University Health Shreveport School of Medicine, 1501 Kings Highway, 3-408C, Shreveport, LA, 71105, USA
| |
Collapse
|
2
|
Transsphenoidal pituitary adenoma resection: do early post-operative cortisol levels predict permanent long-term hypocortisolism? Neurosurg Rev 2021; 45:1353-1362. [PMID: 34545507 PMCID: PMC8976765 DOI: 10.1007/s10143-021-01643-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Revised: 08/31/2021] [Accepted: 09/07/2021] [Indexed: 11/08/2022]
Abstract
Transsphenoidal surgery provides a minimal invasive treatment for pituitary adenoma. Our aim is to evaluate the endocrinological outcomes after adenoma resection focusing on the corticotroph function, and to identify prognostic factors for an impaired hypothalamic–pituitary–adrenal-axis function (HPA) and the reliability of postoperative early morning serum cortisol measurements. We performed a retrospective analysis of all patients treated for pituitary adenoma from April 2006 to January 2019 in our neurosurgical department. Pituitary function was assessed pre- and postoperatively as well as at 6 weeks to 12 weeks and at 1-year follow-up. Two hundred eleven patients were included. Nine percent of the patients recovered from a preoperative adrenal insufficiency, 10.4% developed a new need for hormone substitution, and a long-term deficiency of the hypothalamic–pituitary–adrenal-axis was observed in 30.9%. Cortisol measurements 5 days after surgery had a lower area under the curve (AUC) than cortisol levels detected after 6 to 12 weeks (AUC 0.740 vs. AUC 0.808) in predicting an intact corticotrope function. The cut-off value determined for cortisol measured after 6 weeks was 6.95 µg/dl (sensitivity of 94%, specificity of 68%). Postoperative early morning cortisol levels seem to be less sensitive and specific in predicting long-term corticotroph function than measurements after 6 weeks and 1 year, emphasizing the importance of endocrine follow-up testing.
Collapse
|
3
|
Park EG, Kim EJ, Kim EJ, Kim HY, Kim SH, Yang A. Coexistence of Growth Hormone Deficiency and Pituitary Microadenoma in a Child with Unique Mosaic Turner Syndrome: A Case Report and Literature Review. Diagnostics (Basel) 2020; 10:diagnostics10100783. [PMID: 33020433 PMCID: PMC7600578 DOI: 10.3390/diagnostics10100783] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2020] [Revised: 09/30/2020] [Accepted: 10/02/2020] [Indexed: 01/15/2023] Open
Abstract
Turner syndrome (TS) is a genetic disorder with phenotypic heterogeneity caused by the monosomy or structural abnormalities of the X chromosome, and it has a prevalence of about 1/2500 females live birth. The variable clinical features of TS include short stature, gonadal failure, and skeletal dysplasia. The association with growth hormone (GH) deficiency or other hypopituitarism in TS is extremely rare, with only a few case reports published in the literature. Here, we report the first case of a patient with mosaic TS with complete GH deficiency and pituitary microadenoma, and we include the literature review. During the work-up of the patient for severe short stature, three GH provocation tests revealed peak GH levels of less than 5 ng/mL, which was compatible with complete GH deficiency. Sella magnetic resonance imaging showed an 8 mm non-enhancing pituitary adenoma with mild superior displacement of the optic chiasm. Karyotyping revealed the presence of ring chromosome X and monosomy X (46,X,r(X)/45,X/46,X,psu dic r(X;X)), which indicated a mosaic TS. It is important to consider not only chromosome analyses in females with short stature, but also the possibility of the coexistence of complete GH deficiency accompanying pituitary lesions in TS. In conclusion, the present study reports the first case of GH deficiency and pituitary adenoma in a patient with rare mosaic TS, which extends the genotype-phenotype spectrum for TS.
Collapse
Affiliation(s)
- Eu Gene Park
- Department of Pediatrics, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 56, Dongsu-ro, Bupyeong-gu, Incheon 21431, Korea;
| | - Eun-Jung Kim
- Samsung Medical Center, Department of Laboratory Medicine and Genetics, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea; (E.-J.K.); (E.-J.K.); (H.-Y.K.); (S.-H.K.)
| | - Eun-Jee Kim
- Samsung Medical Center, Department of Laboratory Medicine and Genetics, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea; (E.-J.K.); (E.-J.K.); (H.-Y.K.); (S.-H.K.)
| | - Hyun-Young Kim
- Samsung Medical Center, Department of Laboratory Medicine and Genetics, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea; (E.-J.K.); (E.-J.K.); (H.-Y.K.); (S.-H.K.)
| | - Sun-Hee Kim
- Samsung Medical Center, Department of Laboratory Medicine and Genetics, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea; (E.-J.K.); (E.-J.K.); (H.-Y.K.); (S.-H.K.)
| | - Aram Yang
- Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul 03181, Korea
- Correspondence: ; Tel.: +82-2-2001-1980; Fax: +82-2-2001-1922
| |
Collapse
|
4
|
Laws ER, Penn DL, Repetti CS. Advances and controversies in the classification and grading of pituitary tumors. J Endocrinol Invest 2019; 42:129-135. [PMID: 29858984 DOI: 10.1007/s40618-018-0901-5] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/18/2018] [Accepted: 05/11/2018] [Indexed: 11/30/2022]
Abstract
BACKGROUND Pituitary tumors are common lesions, and they represent the second most frequent primary brain tumor. Their classification has undergone several changes over time. The World Health Organization conducts periodic expert review/consensus meetings and publishes the results as recommendations for changes in classification, based on advances in molecular and genetic advances. This paper summarizes the results of the 2017 WHO Classification, which recommends several important changes. PURPOSE This paper provides a review of the major changes and issues leading to an understanding of the basis for a new pituitary tumor classification. They include the rejection and modification of prior conceptual and pathological characteristics of these neoplasms. There is also considerable concern related to invasive and recurrent pituitary tumors which follow a less benign course than the typical pituitary adenoma. METHODS A review of the outcome data for the previously designated "atypical" pituitary tumor category revealed that the former criteria were not adequate to support their ability to predict with accuracy the clinical course of a given tumor. A similar review was accomplished regarding the role of the p53 tumor suppressor mutation. Again, there was no reliable contribution of p53 status to tumor aggressiveness. Other changes have occurred regarding the cytogenetic lineage of the various subtypes of pituitary adenoma. The transcription factors Pit-1, SF-1, and TPit play a major role in determining tumor subtypes and have become part of the classification criteria. RESULTS These advances now help provide the background for more reliable and consistent classification of pituitary adenomas. Further definition of aggressive characteristics such as cavernous sinus and dural invasion remain to be considered in the quest to make more accurate prognostic projections based on histopathological analysis. CONCLUSIONS The 2017 WHO Classification of Pituitary Tumors provides a more solid basis for accurate and reliable prognostic assessment of these lesions. Further progress undoubtedly will be made as the recommendations of this update are incorporated in to routine use.
Collapse
Affiliation(s)
- E R Laws
- Department of Neurological Surgery, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, BTM, 4th Floor, Boston, MA, 02115, USA.
| | - D L Penn
- Department of Neurological Surgery, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, BTM, 4th Floor, Boston, MA, 02115, USA
| | - C S Repetti
- Department of Neurological Surgery, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, BTM, 4th Floor, Boston, MA, 02115, USA
| |
Collapse
|
5
|
Harary M, DiRisio AC, Dawood HY, Kim J, Lamba N, Cho CH, Smith TR, Zaidi HA, Laws ER. Endocrine function and gland volume after endoscopic transsphenoidal surgery for nonfunctional pituitary macroadenomas. J Neurosurg 2018; 131:1142-1151. [PMID: 30497144 DOI: 10.3171/2018.5.jns181054] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2018] [Accepted: 05/29/2018] [Indexed: 01/22/2023]
Abstract
OBJECTIVE Loss of pituitary function due to nonfunctional pituitary adenoma (NFPA) may be due to compression of the pituitary gland. It has been proposed that the size of the gland and relative perioperative gland expansion may relate to recovery of pituitary function, but the extent of this is unclear. This study aims to assess temporal changes in hormonal function after transsphenoidal resection of NFPA and the relationship between gland reexpansion and endocrine recovery. METHODS Patients who underwent endoscopic transsphenoidal surgery by a single surgeon for resection of a nonfunctional macroadenoma were selected for inclusion. Patients with prior pituitary surgery or radiosurgery were excluded. Patient characteristics and endocrine function were extracted by chart review. Volumetric segmentation of the pre- and postoperative (≥ 6 months) pituitary gland was performed using preoperative and long-term postoperative MR images. The relationship between endocrine function over time and clinical attributes, including gland volume, were examined. RESULTS One hundred sixty eligible patients were identified, of whom 47.5% were female; 56.9% of patients had anterior pituitary hormone deficits preoperatively. The median tumor diameter and gland volume preoperatively were 22.5 mm (interquartile range [IQR] 18.0-28.8 mm) and 0.18 cm3 (IQR 0.13-0.28 cm3), respectively. In 55% of patients, endocrine function normalized or improved in their affected axes by median last clinical follow-up of 24.4 months (IQR 3.2-51.2 months). Older age, male sex, and larger tumor size were associated with likelihood of endocrine recovery. Median time to recovery of any axis was 12.2 months (IQR 2.5-23.9 months); hypothyroidism was the slowest axis to recover. Although the gland significantly reexpanded from preoperatively (0.18 cm3, IQR 0.13-0.28 cm3) to postoperatively (0.33 cm3, IQR 0.23-0.48 cm3; p < 0.001), there was no consistent association with improved endocrine function. CONCLUSIONS Recovery of endocrine function can occur several months and even years after surgery, with more than 50% of patients showing improved or normalized function. Tumor size, and not gland volume, was associated with preserved or recovered endocrine function.
Collapse
Affiliation(s)
- Maya Harary
- 1Computational Neuroscience Outcomes Center (CNOC), Department of Neurosurgery
| | - Aislyn C DiRisio
- 1Computational Neuroscience Outcomes Center (CNOC), Department of Neurosurgery
- 2Icahn School of Medicine at Mount Sinai, New York City, New York; and
| | - Hassan Y Dawood
- 1Computational Neuroscience Outcomes Center (CNOC), Department of Neurosurgery
| | - John Kim
- 3Division of Neuroradiology, University of Michigan, Ann Arbor, Michigan
| | - Nayan Lamba
- 1Computational Neuroscience Outcomes Center (CNOC), Department of Neurosurgery
| | | | - Timothy R Smith
- 1Computational Neuroscience Outcomes Center (CNOC), Department of Neurosurgery
- 5Pituitary and Neuroendocrine Center, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Hasan A Zaidi
- 1Computational Neuroscience Outcomes Center (CNOC), Department of Neurosurgery
- 5Pituitary and Neuroendocrine Center, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Edward R Laws
- 5Pituitary and Neuroendocrine Center, Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
6
|
Abstract
Non-functional pituitary adenomas (NFPAs) are benign tumors of the pituitary gland that do not over-secrete hormonal products, therefore, they are generally detected through symptoms of mass effect, including headache, vision loss, or hypopituitarism. There are multiple pathological subtypes of NFPAs, such as null cell adenomas, silent gonadotrophs, silent somatotrophs, silent corticotrophs, and silent subtype 3, all of which can be classified based on immunohistochemical studies and electron microscopy. Despite these numerous pathological subtypes, surgical resection remains the first-line treatment for NFPAs. Diagnosis is best made using high resolution MRI brain with and without gadolinium contrast, which is also helpful in determining the extent of invasion of the tumor and recognizing necessary sinonasal anatomy prior to surgery. Additional pre-operative work-up should include full laboratory endocrine evaluation with replacement of hormone deficiencies, and ideally, full neuro-ophthalmologic exam. Although transcranial surgical approaches to the pituitary gland can be performed, the most common approach used is the transnasal transsphenoidal approach with endoscopic or microscopic visualization. This approach avoids retraction of the brain and cranial nerves during tumor removal. Surgery for symptoms caused by mass effect, including headaches and visual loss, are successfully treated with surgical resection, resulting in improvement in pre-operative symptoms as high as 90% in some reports. Although the risk of complications is low, major and minor events, such as permanent hypopituitarism, persistent CSF leak, and carotid artery injury can occur at rates ranging from zero to about 9%.
Collapse
Affiliation(s)
- David L Penn
- Department of Neurological Surgery, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, BTM, 4th Floor, Boston, MA, 02115, USA
| | - William T Burke
- School of Medicine, University of Louisville, Louisville, KY, USA
| | - Edward R Laws
- Department of Neurological Surgery, Brigham and Women's Hospital, Harvard Medical School, 60 Fenwood Road, BTM, 4th Floor, Boston, MA, 02115, USA.
| |
Collapse
|
7
|
Toini A, Dolci A, Ferrante E, Verrua E, Malchiodi E, Sala E, Lania AG, Chiodini I, Beck-Peccoz P, Arosio M, Spada A, Mantovani G. Screening for ACTH-dependent hypercortisolism in patients affected with pituitary incidentaloma. Eur J Endocrinol 2015; 172:363-9. [PMID: 25722096 DOI: 10.1530/eje-14-0599] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
CONTEXT Pituitary incidentalomas (PIs) are commonly encountered in clinical practice. The management of these asymptomatic pituitary lesions is still controversial. Systematic screening for subclinical or mild ACTH-dependent hypercortisolism (AH) is not presently recommended, due to the limited data available thus far on the epidemiological and clinical relevance of this condition in patients with PIs. As subclinical hypercortisolism (SH) was considered to be associated with chronic complications of overt cortisol excess, such as hypertension, diabetes, and osteoporosis, this disorder should be diagnosed at the early stage. OBJECTIVE The objective of this study was to evaluate the prevalence of hypercortisolism in a population of subjects with PIs. DESIGN, SUBJECTS, AND METHODS A total of 68 consecutive patients (48 females and 20 males, aged 18-82 years) without clinically overt hypercortisolism, who were referred for evaluation of PIs between January 2010 and March 2013, were prospectively investigated for AH. Pituitary hypercortisolism was diagnosed in the presence of cortisol >50 nmol/l after 1 mg dexamethasone suppression test, non-suppressed ACTH, and the additional finding of one of the following: urinary free cortisol (UFC) >193 nmol/24 h, and midnight serum and salivary cortisol levels >207 and 2.8 nmol/l respectively. RESULTS Among patients with PIs, we found a 7.3% rate of pituitary hypercortisolism diagnosed with biochemical criteria and a 4.4% rate of histologically confirmed AH. CONCLUSIONS Subclinical or mild hypercortisolism may be more common than generally perceived in patients with PIs.
Collapse
Affiliation(s)
- A Toini
- Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy
| | - A Dolci
- Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy
| | - E Ferrante
- Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy
| | - E Verrua
- Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy
| | - E Malchiodi
- Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy
| | - E Sala
- Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy
| | - A G Lania
- Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy
| | - I Chiodini
- Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy
| | - P Beck-Peccoz
- Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy
| | - M Arosio
- Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy
| | - A Spada
- Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy
| | - G Mantovani
- Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy Endocrinology and Diabetology UnitFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza, 35, 20122 Milan, ItalyDepartment of Clinical Sciences and Community HealthUniversity of Milan, Milan, ItalyMultimedica GroupUnit of Endocrine Diseases and Diabetology, San Giuseppe Hospital, Milan, ItalyBIOMETRA DepartmentIRCCS Istituto Clinico Humanitas, University of Milan, Rozzano, Milan, Italy
| |
Collapse
|
8
|
Chen L, Ye H, Wang X, Tang X, Mao Y, Zhao Y, Wu Z, Mao XO, Xie L, Jin K, Yao Y. Evidence of brain tumor stem progenitor-like cells with low proliferative capacity in human benign pituitary adenoma. Cancer Lett 2014; 349:61-6. [DOI: 10.1016/j.canlet.2014.03.031] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2014] [Revised: 03/13/2014] [Accepted: 03/25/2014] [Indexed: 01/08/2023]
|
9
|
Abstract
Primary neoplasms of the pituitary gland are uncommon in children. Physiological enlargement of the gland, however, is universal and can sometimes be confused with a tumor. Due to widespread availability of MR imaging, the number of children referred to pediatric neurosurgeons with an enlarged pituitary associated with nonspecific symptoms, most commonly headache, is increasing. In this review, the authors illustrate two common causes of pituitary enlargement in children, namely physiological hypertrophy of puberty, more commonly seen in females, and secondary hyperplasia caused by hypothyroidism. The importance of early and accurate diagnosis, without recourse to extensive endocrine investigations or inappropriate surgery, is underscored.
Collapse
Affiliation(s)
- Kristian Aquilina
- Department of Neurosurgery, Frenchay Hospital, Bristol, United Kingdom
| | | |
Collapse
|
10
|
Sizova D, Ho Y, Cooke NE, Liebhaber SA. Research resource: T-antigen transformation of pituitary cells captures three novel cell lines in the Pit-1 lineage. Mol Endocrinol 2010; 24:2232-40. [PMID: 20829390 DOI: 10.1210/me.2010-0235] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
We report the establishment of three distinct pituitary-derived murine cell lines generated by targeted T-antigen-induced transformation. The Pit1/0 line expresses pituitary-specific transcription factor-1 (Pit-1) but lacks expression of GH, prolactin (Prl), or TSH, and the Pit1/Prl line is selectively positive for Pit-1 and Prl. The third line, Pit1/Triple, expresses Pit-1 and all three of the Pit-1-dependent hormones: GH, Prl, and TSHβ/glycoprotein hormone α-subunit. The three corresponding transformation events appear to have captured pituitary cells representing: 1) an initial step in the Pit-1(+) lineage, 2) a cell line that corresponds to the differentiated lactotrope, and 3) a novel tri-hormone intermediate that may represent a pivotal step in Pit-1(+) cell lineage differentiation. The documented dependence of the tri-hormone expression in the Pit-1/Triple line on Pit-1 activity supports its potential role in the pathway of pituitary cell differentiation. The presence of a 123-kb human transgene encompassing the hGH locus (hGH/bacterial artificial chromosome) in two of these lines, Pit1/0 and Pit1/Prl, further expands their potential utility to the analysis of gene activation within the hGH gene cluster.
Collapse
Affiliation(s)
- Daria Sizova
- Room 560A Clinical Research Building, 415 Curie Boulevard, Philadelphia, Pennsylvania 19104, USA
| | | | | | | |
Collapse
|
11
|
Keil MF, Stratakis CA. Advances in the Diagnosis, Treatment, and Molecular Genetics of Pituitary Adenomas in Childhood. US ENDOCRINOLOGY 2009; 4:81-85. [PMID: 19936300 PMCID: PMC2779046 DOI: 10.17925/ee.2008.04.02.81] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
- Margaret F Keil
- Office of the Chief, Program on Developmental Endocrinology and Genetics (PDEGEN)
| | | |
Collapse
|
12
|
Keil MF, Stratakis CA. Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics. Expert Rev Neurother 2008; 8:563-74. [PMID: 18416659 PMCID: PMC2743125 DOI: 10.1586/14737175.8.4.563] [Citation(s) in RCA: 103] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Pituitary tumors are rare in childhood and adolescence, with a reported prevalence of up to one per 1 million children. Only 2-6% of surgically treated pituitary tumors occur in children. Although pituitary tumors in children are almost never malignant and hormonal secretion is rare, these tumors may result in significant morbidity. Tumors within the pituitary fossa are mainly of two types: craniopharyngiomas and adenomas. Craniopharyngiomas cause symptoms by compressing normal pituitary, causing hormonal deficiencies and producing mass effects on surrounding tissues and the brain; adenomas produce a variety of hormonal conditions such as hyperprolactinemia, Cushing disease and acromegaly or gigantism. Little is known about the genetic causes of sporadic lesions, which comprise the majority of pituitary tumors, but in children, more frequently than in adults, pituitary tumors may be a manifestation of genetic conditions such as multiple endocrine neoplasia type 1, Carney complex, familial isolated pituitary adenoma and McCune-Albright syndrome. The study of pituitary tumorigenesis in the context of these genetic syndromes has advanced our knowledge of the molecular basis of pituitary tumors and may lead to new therapeutic developments.
Collapse
Affiliation(s)
- Margaret F. Keil
- Office of the Chief, Program on Developmental Endocrinology
& Genetics (PDEGEN)
- Inter-Institute Pediatric Endocrinology Training Program,
National Institutes of Health (NIH) Bethesda, MD20892
| | - Constantine A. Stratakis
- Office of the Chief, Program on Developmental Endocrinology
& Genetics (PDEGEN)
- Section on Endocrinology & Genetics (SEGEN), PDEGEN,
National Institute of Child Health and Human Development (NICHD)
- Inter-Institute Pediatric Endocrinology Training Program,
National Institutes of Health (NIH) Bethesda, MD20892
| |
Collapse
|
13
|
Gola M, Doga M, Bonadonna S, Mazziotti G, Vescovi PP, Giustina A. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects. Pituitary 2006; 9:221-9. [PMID: 17036195 DOI: 10.1007/s11102-006-0267-0] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Hypothalamic GHRH is secreted into the portal system, binds to specific surface receptors of the somatotroph cell and elicits intracellular signals that modulate pituitary GH synthesis and/or secretion. Moreover, GHRH is synthesized and expressed in multiple extrapituitary tissues. Excessive peripheral production of GHRH by a tumor source would therefore be expected to cause somatotroph cell hyperstimulation, increased GH secretion and eventually pituitary acromegaly. Immunoreactive GHRH is present in several tumors, including carcinoid tumors, pancreatic cell tumors, small cell lung cancers, endometrial tumors, adrenal adenomas, and pheochromocytomas which have been reported to secrete GHRH. Acromegaly in these patients, however, is uncommon. The distinction of pituitary vs. extrapituitary acromegaly is extremely important in planning effective management. Regardless of the cause, GH and IGF-1 are invariably elevated and GH levels fail to suppress (<1 microg/l) after an oral glucose load in all forms of acromegaly. Dynamic pituitary tests are not helpful in distinguishing acromegalic patients with pituitary tumors from those harbouring extrapituitary tumors. Plasma GHRH levels are usually elevated in patients with peripheral GHRH-secreting tumors, and are normal or low in patients with pituitary acromegaly. Unique and unexpected clinical features in an acromegalic patient, including respiratory wheezing or dyspnea, facial flushing, peptic ulcers, or renal stones sometimes are helpful in alerting the physician to diagnosing non pituitary endocrine tumors. If no facility to measure plasma GHRH is available, and in the absence of MRI evidence of pituitary adenoma, a CT scan of the thorax and abdominal ultrasound could be performed to exclude with good approximation the possibility of an ectopic GHRH syndrome. Surgical resection of the tumor secreting ectopic GHRH should be the logical approach to a patient with ectopic GHRH syndrome. Standard chemotherapy directed at GHRH-producing carcinoid tumors is generally unsuccessful in controlling the activated GH axis. Somatostatin analogs provide an effective option for medical management of carcinoid patients, especially those with recurrent disease. In fact, long-acting somatostatin analogs may be able to control not only the ectopic hormonal secretion syndrome, but also, in some instances, tumor growth. Therefore, although cytotoxic chemotherapy, pituitary surgery, or irradiation still remain available therapeutic options, long-acting somatostatin analogs are now preferred as a second-line therapy in patients with carcinoid tumors and ectopic GHRH-syndrome.
Collapse
Affiliation(s)
- Monica Gola
- Endocrine Section, Department of Internal Medicine, University of Brescia, Brescia, Italy
| | | | | | | | | | | |
Collapse
|
14
|
Miyai S, Yoshimura S, Iwasaki Y, Takekoshi S, Lloyd RV, Osamura RY. Induction of GH, PRL, and TSHβ mRNA by transfection of Pit-1 in a human pituitary adenoma-derived cell line. Cell Tissue Res 2005; 322:269-77. [PMID: 16133148 DOI: 10.1007/s00441-005-0033-z] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2005] [Accepted: 05/25/2005] [Indexed: 10/25/2022]
Abstract
The functional development of pituitary cells depends on the expression of a combination of transcription factors and co-factors. Pituitary-specific transcription factor-1 (Pit-1) is required for the expression of growth hormone (GH), prolactin (PRL), and the thyroid-stimulating hormone beta subunit (TSH beta) and acts synergistically with the estrogen receptor (ER) and GATA-binding protein 2 (GATA-2) to induce PRL and TSH beta expression, respectively. The glycoprotein hormone alpha subunit (alpha SU) is the first hormone to be expressed during pituitary development. In addition to being expressed in follicle-stimulating hormone, luteinizing hormone (LH), and TSH cells, alpha SU is reported to co-localize with GH in pituitary cells. These findings have led to the suggestion that the expression of Pit-1 in cells of the alpha SU-based gonadotropin cell lineage might also lead to the expression of GH. In this study, we transfected HP 75 cells (derived from a human non-functioning pituitary adenoma that expressed alpha SU and LH beta) with Pit-1 by using an adenovirus FLAG-Pit-1 construct. Most of the transfected cells expressed GH mRNA, with fewer cells expressing PRL and TSH beta mRNA. The HP 75 cells expressed the genes for ER and GATA-2, thus allowing their expression of GH, PRL, and TSH beta mRNA in response to Pit-1. These results support the hypothesis that GH can be induced in cells that possess an active alpha SU gene and shed light on the basic molecular mechanism that drives the development of GH, PRL, and TSH beta expression in the alpha SU-based gonadotroph lineage.
Collapse
Affiliation(s)
- Shunsuke Miyai
- Department of Pathology, Tokai University School of Medicine, Bohseidai Isehara Campus, Kanagawa 259-1193, Japan.
| | | | | | | | | | | |
Collapse
|
15
|
|
16
|
Affiliation(s)
- J A Jane
- Department of Neurosurgery, University of Virginia, Charlottesville 22908, USA
| | | |
Collapse
|
17
|
Abstract
Prolactinomas constitute the largest group of pituitary adenomas in autopsy series. However, their relative incidence in recent surgical series is much less impressive since medical treatment with dopamine agonists is routinely employed, which in many cases leads to tumor shrinkage and normalization of prolactin levels. The clinical symptoms of hyperprolactinemia are menstrual dysfunction and galactorrhea in women and loss of libido and potency in men. Prolactinomas may present also as space occupying sellar mass lesions impinging on the adjacent structures like the pituitary gland, cavernous sinus and optic nerves. The standard primary treatment is medical by dopamine agonists. Prolactinomas are the prototype of tumors, the growth of which can be reliably and safely inhibited by specific drugs other than cytostatic chemotherapy. These unfortunately have side effects, like orthostatic hypotension, nausea and vomiting. The effects induced by dopamine agonists are suppressive but not tumoricidal. Thus, the therapeutic effect is only maintained as long as the drug is administered. Consequently. in most cases, treatment has to be continued life-long with a few exceptions, in whom normoprolactinemia persists even after discontinuation of dopamine agonists. Main indications of surgery in prolactinomas are intolerance of the medication, and tumors not responding to dopamine agonists. Occasionally, these may ultimately require radiation therapy. Remission rates in large series of surgically treated prolactinomas vary between 54% and 86%. In our consecutive series of 540 surgically treated prolactinomas, the normalization rate after transsphenoidal surgery basically depended on the preoperative prolactin levels, tumor size and extension. The remission rate of 82% in microprolactinomas with initial prolactin levels <200 ng/ml would even in small adenomas make one consider surgical treatment as an interesting alternative to long-term medical treatment.
Collapse
Affiliation(s)
- P Nomikos
- Department of Neurosurgery, University of Erlangen-Nürnberg, Germany.
| | | | | |
Collapse
|
18
|
Abstract
Soon after the initial description of acromegaly in the late 19th century, neurosurgeons performed the first operative procedures for the disease. Transcranial procedures eventually yielded to the transsphenoidal approach. Reasonably effective medical therapy was introduced in the 1970s and pharmacological progress continues to be realized. It is now recognized that excess growth hormone is associated with significant morbidity and mortality and that biochemical remission improves outcome. Although medical and radiation treatments offer useful adjuncts, surgery provides optimal results.
Collapse
Affiliation(s)
- J A Jane
- Department of Neurosurgery, University of Virginia, Charlottesville, USA
| | | | | |
Collapse
|
19
|
Abstract
This brief review summarizes various schemes which were introduced to classify pituitary tumors of adenohypophysial origin. Many different classifications were proposed. Pathologists prefer classifications based on the morphologic features of tumor cells. The gold standard is the light microscopic study of hematoxylin-eosin stained sections of formalin fixed and paraffin-embedded tissues. For correlation between hormone production, secretory activity and cytogenesis, immunohistochemical and transmission electron microscopic investigation is needed. We are convinced that in the future, molecular and genetic techniques will also be applied. We present here our five-tier scheme for classification of pituitary tumors which was accepted by the 'World Health Organization International Histological Classification of Tumours'. This classification takes into consideration the clinical and laboratory findings, imaging results, histologic, immunocytochemical and ultrastructural features of tumor cells. Despite several recent attempts to assess the growth rate, aggressiveness and invasiveness of pituitary tumors, more work is required to draw conclusions on their prognosis.
Collapse
Affiliation(s)
- K Kovacs
- Department of Laboratory Medicine, St. Michael's Hospital, University of Toronto, Ontario, Canada.
| | | | | |
Collapse
|
20
|
Abstract
Many growth factors are expressed in normal pituitary cells and pituitary tumors. They are involved in gene expression for pituitary hormones and in cell proliferation. Some appear to be important for prognosis or treatment. Strong overexpression of some growth factors may indicate a more rapid growth. The significance of the different growth factors for pituitary function and pathology is discussed.
Collapse
|
21
|
Affiliation(s)
- R Fahlbusch
- Neurochirurgische Klinik, University of Erlangen-Nürnberg, Germany.
| |
Collapse
|
22
|
Abstract
The complex range of pituitary regulatory mechanisms reviewed here underlies the critical function of the pituitary in sustaining all higher life forms. Thus, the ultimate net secretion of pituitary hormones is determined by signal integration from all three tiers of pituitary control. It is clear from our current knowledge that the trophic hormone cells of the anterior pituitary are uniquely specialized to respond to these signals. Unravelling their diversity and complexity will shed light upon the normal function of the master gland. Understanding these control mechanisms will lead to novel diagnosis and therapy of disordered pituitary function (357).
Collapse
Affiliation(s)
- D Ray
- Cedars-Sinai Research Institute, UCLA School of Medicine 90048-1865, USA
| | | |
Collapse
|
23
|
Abstract
Insulin-like growth factor (IGF)-l and IGF-ll peptides as well as their mRNAs are produced in many organs, including the pituitary. Although IGFl and IGFII peptides are localized in endocrine cells of the anterior pituitary, IGF-l mRNA can be detected throughout the adenohypophysis, and IGF-ll mRNA is abundant in intermediate and neural lobes. It is well-established that both circulating and intrinsic IGF-l are negative regulators of pituitary GH production. Other functions of intrinsic IGFs in normal and tumorous pituitary are just emerging. IGF-l may play a role in the stimulation of PRL synthesis and mediation of proliferative effects of estrogen on lactotroph. Compared with IGF-l, the function of IGE-Il has not been clarified so far. The growth-promoting actions of IGFs are mediated by IGF-l receptor. The role of local and circulating IGFBPs in pituitary are not yet documented. IGFBPs in other tissues have inhibitory and stimulatory effects on IGFs, and can act independently from the IGFs as well. IGFs have been reported to promote cell proliferation in many tumors. However, the extent to which IGFs contribute to pituitary tumor development and growth remains obscure.
Collapse
|